European Primary Care Cardiovascular Society

The future of CV medicine: anti-inflammation

10' education - Mar. 5, 2021 - Prof. Paul Ridker, MD - Boston, MA, USA

Video navigation menu

  • Residual inflammatory risk 0:42
  • Findings from the CANTOS trial 1:57
  • Findings with colchicine in patients with chronic atherosclerosis 3:11
  • Colchicine in those with ACS and acute MI  7:31
  • Anticipated guideline recommendations 11:25

Do you agree that the time has come to give colchicine to patients with stable atherosclerotic disease?

  • Yes
  • No

Educational information

This video was recorded in response to a recent publication of a subanalysis of COLCOT in Eur Heart J.


Dr. Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston, MA, USA.


The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: